A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer

Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.


Innovative Cellular Therapeutics

Status of enrollment

Accepting new patients

Ages Eligible for Study

Adults aged 18 and older

Genders Eligible for Study

Female and Male

Disease indication

Colorectal Cancer

Principal Investigator

Bridget Keenan, MD, PhD


Harika Gopi

[email protected]


Additional study eligibility details can be found at UCSF Clinical Trials.